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Background: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally
morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast
Asia, and particularly the northeast of Thailand, has by far the highest incidence of CCA worldwide with 135.4 per
100,000 among males and 43.0 per 100,000 among females being reported in Khon Kaen Province. Most patients
are first seen during late stage disease with 5-year survival being less than 10 %. Starting in 1984, control and
prevention strategies have been focused on health education. Although early detection can substantially increase
5-year survival, there are currently no strategies to increase early diagnosis.
Methods/design: The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study
comprising two cohorts- the screening and the patient cohorts. For the screening cohort, ultrasound examination
will be carried out regularly at least annually to determine whether there is current bile duct and/or liver pathology
so that the optimal screening program for early diagnosis can be established. This cohort is expected to include at
least 150,000 individuals coming from high-risk areas for CCA. For the patient cohort, it is estimated that about
25,000 CCA patients will be included during the 5-year recruitment period. All CCA patients will be treated
according to routine clinical care and followed so that effective surgical treatment can be formulated. This cohort
is indeed a conventional cancer registry. Thus, CASCAP is an ongoing project in which the number of participants
changes dynamically.
Discussions: This is the first project on CCA that involves screening the at risk population at the community
level. At the time of preparing this report, a total of 85,927 individuals have been enrolled in the screening
cohort, 55.0 % of whom have already undergone ultrasound screening, and 2661 CCA cases have been enrolled
in the patient cohort. Among the participants of the screening, whose mean age was 53.8 ± 9.8 years, 55.6 %
were female, 77.5 % attained primary school as the highest level of education, 79.9 % were farmers, 29.9 %,
reported having relatives with CCA, 89.1 % had eaten uncooked fish, and 42.2 % of those who had been tested
for liver fluke were found to be infected.
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Cholangiocarcinoma (CCA) is a biliary duct cancer that
commonly invades surrounding liver tissue [1]. It rep-
resents the second most common primary hepatic ma-
lignancy, comprising 30 % of primary hepatic tumors
worldwide, and has very high mortality rates, primarily
due to late detection [2, 3]. Both intra- and extrahepatic
forms occur [1, 4]. Incidence appears to be increasing
worldwide including in Europe and the USA [4–6], al-
though this is dependent of geographical locality. In the
USA, the annual incidence was 2000–3000 cases [7]. In
Europe, the rates of primary liver cancer have declined,
while those for intrahepatic CCA have increased through-
out the European Union by 9 % from1996 to 2008. Recent
developments in CCA staging have been based mainly
on hepatocellular carcinoma and have failed to stratify
CCA patients adequately and appropriately, particularly
with respect to tumor size [8].
The area with by far the highest incidence of CCA
worldwide is along lower Mekong area of Southeast
Asia. This is the distributional area of the liver fluke
Opisthorchis viverrini, which is classified as a class one
carcinogen and is a major risk factor for developing
CCA in this area [9]. Infection occurs via the consumption
of raw or undercooked freshwater fish belonging to the
carp family [10]. The countries bordering the Mekong
have an estimated 90 million people at risk of infection
with an estimated 10 million being infected, although reli-
able data are currently only available from Thailand and,
in part, Lao PDR [11, 12], while there are currently no reli-
able data for Cambodia and southern Vietnam.
Treatment options include liver resection or trans-
plantation and radiation therapy [13–16]. Although, the
general prognosis is poor, with low 5-year survival rates
of usually less than 20 % [17–21], a 65 % cure rate may
be achieved in some cases with perihilar cholangiocarci-
noma that were treated with neo-adjuvant therapy followed
up by liver surgery [22]. There is increasing evidence that
early diagnosis leading to liver resection can substantially
improved the patient’s chances of survival and quality of
life [17, 23, 24]. However, strategies for determining the
main population at risk and thus for developing an effect-
ive screening program remain to be developed.
Thailand has an estimated eight million infected indi-
viduals [25], with an incidence reaching up to 87.7 per
100,000 in males and 36.3 per 100,000 in females [26],
in the northeast of the country which has the highest in-
cidence of CCA worldwide [27]. Although there are vari-
ous estimates of the total number of cases occurring
annually, a conservative estimate suggests that 20,000 or
more deaths/year occur due to intra- and extra-hepatic
CCA in the northeast of Thailand alone [28]. This mor-
tality is directly related to difficulties in diagnosing the
disease at an early stage when surgical cure is possible.Given the poor prognosis due to late-stage discovery of
the disease, and the fact that CCA commonly manifests at
or after the age of 40, with males being more commonly
infected than females, not only is the patient directly af-
fected, but the family for which he or she is responsible is
also liable to socio-economic hardship [29].
The Cholangiocarcinoma Screening and Care Program
(CASCAP) was developed at the Medical Faculty of
Khon Kaen University in cooperation with the Cholangio-
carcinoma Foundation, Thailand. It represents the most
detailed and comprehensive study of the application and
optimization of screening methods for the early diagnosis
of CCA combined with treatment and follow-up world-
wide. It includes a sophisticated data collection and ana-
lysis system that can be used to determine government
policy for the treatment and control of CCA not only
within Thailand but also in other Mekong countries.
CASCAP has multiple aims in addition to developing
a strategy for diagnosing early-stage CCA. It will in-
crease awareness of CCA in the at risk population and
by doing so reduce the costs of screening. It will reduce
the incidence of CCA by determining which individuals
are at high risk based on precancerous pathology and
following them up. As CASCAP data are collected both
longitudinally as well as a cross-sectionally, progressive
changes in the bile duct and liver of individuals can be
monitored. Once diagnosed, patients will receive the
best available treatment. They will then be followed-up
and provided with the best supportive care and clinical
assessment until the end of life.
Although the CASCAP program is health care ori-
ented, the data collected represent a massive research
database for scientific monitoring and evaluation, and in
particular the assessment of long-term changes in the
liver and the bile duct, the rate of early detection, and
long-term clinical outcome of the patients in response
to various medical interventions.
The procedures defined by CASCAP are ultimately
aimed at being adopted as part of routine health-care
practice. All core data items are part of the routine data
collection at all cancer hospitals in the northeastern region
of Thailand and later throughout the Mekong region.
CASCAP serves as an innovative and comprehensive ap-
proach to combat CCA in the region.
Methods/design
Design overview
CASCAP is a prospective cohort study. Two cohorts
have been defined, one for determining who should be
screened and the other for patients diagnosed as having
CCA. The screening cohort, characterized in the upper
zone of Fig. 1, is expected to include at least 150,000 in-
dividuals coming from high-risk areas for CCA, includ-
ing the self-enrolment of persons who feel that they are
Fig. 1 Workflow of the Cholangiocarcinoma Screening and Car Program (CASCAP). CCA = cholangiocarcinoma, U/S = ultrasonography, CT = computed
tomography, MRI =magnetic resonance imaging, MRCP =magnetic resonance cholangiopancreatography
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Table 1 Data being collected
CCA-01: Demographic information form: Enrollment
1. Place of resident
2. Date of birth
3. Gender
4. Education
5. Occupation
6. Number of stool examination for liver fluke infection in the past
7. Being ever had found to be infected by liver fluke
8. Number of occasions being treated for liver fluke infection
9. Relatives diagnosed with cholangiocarcinoma
10. Cigarette smoking
11. Alcohol drinking
12. Being ever had chronic alcoholic toxicity
13. Being ever had eaten uncooked or fermented fish (specifically, fresh
water with scales)
14. Underlying diseases
CCA-02: Ultrasound form
15. Liver
15.1) Parenchymal ECHO (Normal, Abnormal)
15.2) Fatty liver (Mild, Moderate, Severe)
15.3) Periductal fibrosis (PDF1, PDF2, PDF3)
15.4) Cirrhosis
15.5) Liver Mass (No, Single Mass, Multiple Masses)
15.6) Liver mass characteristics (High echo, Low echo, Mixed echo,
Liver cyst)
15.7) Liver mass size
15.8) Liver mass side (left, right)
15.9) Dilated Bile Duct (No dilated duct, Right lobe, Left lobe,
Common bile duct)
16. Gallbladder
16.1) Gallbladder findings (Normal, Abnormal)
16.2) Gallbladder wall thickening (Focal, Diffuse) and size
16.3) Gallbladder polyp (Single, Multiple) and size
16.4) Gallbladder mass (Single, Multiple) and size
16.5) Gallstone (None, Single, Multiple)
16.6) Being post cholecystectomy
17. Kidney
17.1) Kidney (Normal, Abnormal)
17.2) Renal cyst (None, Right, Left)
17.3) Parenchymal change (None, Right, Left)
17.4) Renal stone (None, without hydronephrosis, with
hydronephrosis)
17.5) Renal stone (None, Right, Left)
17.6) Being post nephrectomy
18. Other Finding (Ascites, Splenomegaly, Others)
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clude all endemic northeastern Thais of 40 years or over
with any of the following: ever been infected by or
treated for liver flukes or known to have eaten uncooked
freshwater fish with scales. Once consent has been ob-
tained, the participants will be enrolled in the program
and their baseline information collected. If CCA has
been diagnosed, the individual will automatically be
moved to the second, patient cohort, characterized in
the lower zone of Fig. 1.
After the baseline characteristics have been recorded,
an ultrasound examination will be carried out (the upper
zone of Fig. 1) to determine whether there is current bile
duct and/or liver pathology. Patients with liver mass or
bile duct dilatation will be directed to confirmatory diag-
nostic tests and, if CCA is confirmed, they will be trans-
ferred to the patient cohort (the lower zone of Fig. 1).
The patient cohort will include all CCA patients diag-
nosed in the region over a 5-year duration, with an esti-
mated number of 5000 histologically proven new cases
per year or 25,000 in the five-year recruitment period. It
will include individuals diagnosed from the screening co-
hort, as well as new patients diagnosed at the nine
tertiary-care hospitals participating in the CASCAP
study. After diagnosis, the treatment regime will be de-
termined and recorded. These patients will be treated
according to the routine care procedures of the hospi-
tals. Follow-up treatment will be recorded. Patients will
be followed-up until the end of life.
Follow-up schedule
For the screening cohort, participants will undergo ultra-
sonography every 12 months if the findings are negative,
and every 6 months if the diagnosis is positive for either
periductal fibrosis of the bile duct, or fatty liver, or cir-
rhosis. They will be immediately referred to CT or MRI
if they have liver mass or bile duct dilatation.
For the patient cohort, treatment follow-up will be
based on local routine care every 3 month for the first
year and every 6 month thereafter. CASCAP will follow
up all patients every year to update information on their
health.
Data collection
There are six data collection forms indicated as CCA-01
to CCA-05 according to each phase as shown in Fig. 1,
with details of the parameters being collected shown in
Table 1. These include the Demographic Information
and Enrollment Form (CCA-01), Ultrasound Form
(CCA-02), Confirmatory Diagnosis Form (CCA-02.1),
Diagnosis and Treatment at the 1st visit (CCA-03),
Follow-up Treatment Form (CCA-03.1), Final Staging
Diagnosis (CCA-04), and Post Operation Follow-up
Form (CCA-05).
Table 1 Data being collected (Continued)
CCA-02.1: Confirmatory diagnosis form
19. Mode of confirmatory Diagnosis (CT, MRI, Others)
20. Finding and location of tumor in the bile duct (Normal, Intrahepatic,
Perihilar, Distal, Other diseases)
21. Side of intrahepatic CCA, if any (Right lobe, Left lobe)
22. Type of perihilar CCA (BC 1, BC 2, BC 3a, BC 3b, BC 4)
23. Tumor morphology
23.1) Mass forming (nodular) and size
23.2) Periductal infiltrating type
23.3) Intraductal type and size
23.4) Mixed type
24. Hepatic artery (Normal, Encasement)
25. Hepatic vein (Normal, Encasement)
26. Portal vein (Normal, Encasement)
27. Lymph node (Normal, Positive node along hepatoduodenal
ligament, Positive at others nodes)
28. Adjacent organ involvement / Distant metastases (No, Yes)
29. Type of organ involvement, if any (Lymph node, Lungs and pleura,
Bone, Brain, Peritoneum, Others)
CCA-03: Diagnosis and treatment at the 1st visit
30. Surgical Treatment (Done, Not done)
31. Tumor site (Intrahepatic CCA, Perihilar CCA, Distal CCA, Other
diseases)
32. Clinical Staging (TNM)
33. Treatment protocol being implemented
33.1) Surgery (Liver resection, Hilar resection, Bypass, Exploratory
laparotomy +/− biopsy, Whipple’s operation)
33.1) Chemotherapy (Adjuvant, Palliative)
33.1) PTBD (Pre-op therapy, Palliative)
33.1) Endoscopic Stent (Pre-op therapy, Palliative)
33.1) Medication Treatment (IV, Antibiotics, Others)
34. Best supportive Treatment (Yes, No)
35. Results (Death, Discharged, Referred to other hospitals)
CCA-03.1: Follow-up treatment form
36. Treatment protocol being implemented
36.1) Surgery (Liver resection, Hilar resection, Bypass, Exploratory
laparotomy +/− biopsy, Whipple’s operation)
36.1) Chemotherapy (Adjuvant, Palliative)
36.1) PTBD (Pre-op therapy, Palliative)
36.1) Endoscopic Stent (Pre-op therapy, Palliative)
36.1) Medication Treatment (IV, Antibiotics, Others)
37. Best supportive Treatment (Yes, No)
38. Results (Death, Discharged, Referred to other hospitals)
CCA-04: Final staging diagnosis
39. Tumor site (Intrahepatic bile duct (CCA, C221), Perihilar (CCA, C240),
Distal (CCA, C241), Others, non-specified)
40. Marginal status (R0-free margin, R1-not free margin, microscopic,
R2-not free margin, gross finding)
Table 1 Data being collected (Continued)
41. Lymph node status (N0-no metastasis, N1-metastasis hepatoduodenal
node, node 8 or 12, N2-metastasis aortocarval, node 9, 13, 16)
42. Histology (Non papillary, Papillary non invasive, Papillary invasive,
Other type)
43. CCA Staging (Stage 0, I, II, IIIA,IIIB, IVA, IVB, Unknown)
44. Metastasis (No data, None, Lymph node, Lungs and pleura, Bone,
Brain, Peritoneum, Liver, Others)
CCA-05: Post operation follow-up form
45. Date and mode of follow-up (By hospital visit, By phone call)
46. Status of the patient (Health, Recurrent, Progress, Withdrawn
consent, Loss to follow-up >3 months after the appointment, Dead
and Cause of dead)
47. Being treated at other hospitals prior to this visit (Yes, No)
48. Co-morbidity (None, Diabetes, Hypertension, Heart disease, Others)
49. Complications (None, Cholangitis, Liver failure, Pancreatitis,50. Renal
failure, Pleural effusion, Intra abdominal bleeding, Wound infection,
Ascites, Prolonged bile leakage, Others
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With a targeted sample size of 150,000 participants to be
screened for CCA, we expect to detect early stage CCA at
a rate as low as one per 1000 with a precision of no more
than ±0.16 per 1000. A minimum of 1500 early stage CCA
patients is sufficient to demonstrate the efficacy of the
various treatment protocols provided to this cohort com-
pared to the patient group at late stage detection, as well
as comparing across the treatment protocols. At the end
of the recruitment period, we expect to achieve a total
sample size of 25,000 patients with some stage of the dis-
ease. This sample size would allow us to calculate a hazard
ratio (HR) of at least 1.5, with a power of greater than
99 % for progression-free survival comparing either across
treatment protocols or disease stages. This was estimated
based on an assumption of the overall anticipated event
rate of 0.5 with a correlation among covariates of 0.1 and
based on using cox regression as the statistical method.
For additional statistical analysis, we will estimate the
rate of CCA together with its 95 % confidence interval
(95%CI), particularly for early stage CCA, as well as the
corresponding rate for each relevant subgroup. Survival
analysis will be used to obtain survival profiles, including
time to detection, time to disease recurrence or death, sur-
vival probability at 1–5 years, and hazard ratios with their
95%CIs. For these purposes, Kaplan-Meier methods and
cox regression will be used. All analyses will be performed
using Stata version 13 (StataCorp, College Station, TX).
Significance level is set as 0.05 and all statistical tests will
be two-sided.
Ethics and good clinical practice
This study will be performed according to the principles of
Good Clinical Practice [Chapter 2 of the ICH Harmonized
Khuntikeo et al. BMC Cancer  (2015) 15:459 Page 6 of 8Tripartite Guideline for Good Clinical Practice (GCP)], the
declaration of Helsinki, and national laws and regulations
about clinical studies. The CASCAP was approved by the
Khon Kaen University Ethics Committee for Human Re-
search on February 9, 2013. The first participant was en-
rolled on March 5, 2013.
Discussions
Cohort profiles
CASCAP is an ongoing project in which the number of
participants changes dynamically. For the purpose of this
preliminary report, the data at the completion of the first
year of the project were analyzed and the characteristic
of participants at baseline were reported.
A total of 85,927 individuals were enrolled with a
mean age of 53.8 ± 9.8 years of whom 55.6 % were female
(Table 2). About three quarters, 77.5 %, had attained pri-
mary school as the highest level of education, and 79.9 %
were farmers. More than half, 55.9 % had previously been
tested for liver fluke infection. Among the 47,258 par-
ticipants who had been tested, 42.2 % were found to be
infected. About a quarter, 29.9 %, reported they have
relatives with CCA and 89.1 % had previously eaten un-
cooked or fermented fish (specifically, freshwater fish
with scales).
At the time of preparing this report, there were 47,285
(55.0 %) participants who had undergone ultrasono-
graphic screening and 2661 CCA cases have been en-
rolled in the patient cohort (data not shown).
Strengths and weaknesses
Strengths of the CASCAP study include the novelty and
uniqueness of the project. This is the first project on
CCA that involves screening the at risk population at the
community level. The initial screening involved ultrason-
ography with the images being evaluated independently by
at least two trained radiologists.
The project incorporates two cohorts which provided
the largest pool of CCA risk participants and CCA pa-
tients worldwide. In addition, it allows for long term
monitoring and the ability to discovering rare events,
such as the development of CCA. For the screening co-
hort, participants were recruited at the community level
by their local health service providers, which allows for
maximizing follow-up rates, as well as the sustainability
of the project. The patient cohort covers a wide disease
spectrum, in particular early stage CCA, whereas current
practice almost always encounters patients at the ad-
vanced, incurable stage. All CCA patients in the cohort
were histologically confirmed. All major hospitals in the
northeast region are actively involved in the program
and treatment is based on the routine medical care re-
gime of each hospital. This allows not only sustainability,
but also assessment of the effectiveness of the varioustreatment protocols. The current disease staging practice
can then be evaluated and revised.
The sustainability of the project is promising. Intensive
efforts by CASCAP to raise the awareness of CCA, after
this usually fatal disease had been neglected for more
than three decades, have been successful. In December
2014, a year after the initiation of CASCAP, combatting
liver fluke infection and cholangiocarcinoma were offi-
cially declared to be part of the national health policy.
All health care units, the local municipality and commu-
nity are actively involved in the screening program. Ac-
tivities under this theme have a high level of support
from the National Health Security Office. In addition,
CASCAP has established international collaborations with
many institutes, including Imperial College in England,
the German Cancer Research Foundation, the National
University of Singapore, the Royal Veterinary Institute and
Karlsruhe Institute of Technology, as well as international
funding agencies such as the Wellcome Trust, Center for
Global Health and the German Federal Ministry of Educa-
tion and Research. In an international context, active in-
volvement has begun within the diagnostic and training
program. For instance, hospitals and care units in Laos
PDR has established an initial collaboration. CASCAP is
also embedded in the Cholangiocarcinoma Foundation of
Thailand and collaborates with The Alan Morement Me-
morial Fund (AMMF), the only charity body for CCA in
England.
The current weaknesses of the CASCAP include the
fact that the awareness of the health risk in participants
people and patients is still limited. Based on the percep-
tion of the fatal outcome of CCA for late stage patients
(“you have to die of something anyway”) is common. In
addition, a large proportion of the at risk population are
not aware that they are in fact at risk and do not know
where they can receive assistance e.g. screening and
treatment. A large proportion of the community, the
health care providers and doctors do not fully under-
stand that CCA is a curable disease is treated at an early
stage.
Data archival
Data is being collected using a web-based application at
www.cascap.in.th. A software package “CASCAP Tools”
has been designed for this web application. This is avail-
able to health and medical professionals throughout the
region. Health care facilities are welcome to freely apply
for an account. Health care personnel at the village level
enroll at risk populations under their responsible health
service area into CASCAP Tools. This allows them to
monitor, at any time, whether their participants had
undergone U/S monitoring, had been diagnosed, treated,
and the clinical outcome until the end of life. This is
made possible using the 13-digit citizen identification
Table 2 Demographic and baseline information collected on
enrollment
Characteristic on enrolment n (%)
Gender
Male 38,066 (44.4)
Female 47,739 (55.6)
Age (years)
40–49 33,595 (39.1)
50–59 29,292 (34.1)
60–69 16,724 (19.5)
70+ 6316 (7.3)
Mean (Standard deviation) 53.82 (9.77)
Median (Minimum : Maximum) 52 (40 : 100)
Educational attainment
No formal education 1134 (1.3)
Primary school 66,000 (77.5)
Secondary school level 1 6194 (7.3)
Secondary school level 2 6639 (7.8)
College 1127 (1.3)
Bachelors degree 3154 (3.7)
Masters degree or higher 931 (1.1)
Occupation
Unemployed 2787 (3.3)
Farmer 68,060 (79.9)
Labor 5378 (6.3)
Self-employed 2594 (3.0)
Government/state enterprise 4198 (4.9)
Others 2189 (2.6)
Number of occasions of fecal examination
for liver fluke infection
0 31,620 (37.2)
1 33,667 (39.6)
2 9806 (11.5)
3 3033 (3.6)
More than 3 3504 (4.1)
Cannot remember 3426 (4.0)
Being found to be infected by liver fluke
Never tested 32,121 (38.0)
Tested but negative 27,296 (32.3)
Tested and positive 19,962 (23.6)
Cannot remember 5161 (6.1)
Rate of liver fluke infection 47,258 (42.2)
Relatives diagnosed with cholangiocarcinoma
None 59,562 (70.1)
Yes 25,445 (29.9)
Table 2 Demographic and baseline information collected on
enrollment (Continued)
Ever eaten uncooked or fermented fish
(specifically, freshwater with scales)
No 9271 (10.9)
Yes, current or previous 75,816 (89.1)
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However, only authorized health personnel can access to
the data. General users can access only the summary re-
port without being able to view the individual records. Re-
searchers are welcome to use the individual records that
made available under permission of the CASCAP Data-
base Committee. They can request the data by submitting
a Data Analysis Plan Proposal at http://www.cascap.in.th/
damus/analysis_plan.php.
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